On March 26th, the Secretariat of the Sub-Technical Committee of Tissue Engineering Medical Devices received a notice from the International Department of Standardization (ISO), and China served as the International Organization for Standardization/Surgical Implants and Orthopaedic Devices Standardization Technical Committee/Organization Engineering Medical Products Division. The active member states (P members) of the Technical Committee (ISO/TC150/SC7) have already completed registration and have obtained the right to vote internationally for ISO/TC150/SC7 standardization activities.

The International Organization for Engineering Medical Products sub-committee was established in 2007 and has 12 member countries. China is the 13th and is the first member country of developing countries in Asia. This is of great significance for our country to rank among advanced countries, to cross relevant technical barriers, and to participate in fair competition in international trade in this technology field. In December 2012, the China National Institute for Food and Drug Control (hereinafter referred to as the Central Institute for Inspection and Quarantine), as the organization unit of the Technical Subcommittee of the Engineering Medical Devices Products Subcommittee of the National Standardization Technical Committee of Surgical Implants and Orthopaedic Devices, completed the Subcommittee's Prepare construction work. On January 14, 2013, the China National Institute of Standardization officially applied to the National Standardization Management Committee for membership in ISO/TC150/SC7. On March 20th, the National Standardization Management Committee formally agreed that China Inspection and Testing Institute should undertake the domestic technical counterpart of ISO/TC150/SC7. Unit, and participate in the relevant activities of the Subcommittee as a member of P (No. 42 (2013), SPC Office).

As an interdisciplinary multidisciplinary technology, organizational engineering has developed rapidly in the past decade, bringing revolutionary innovation to traditional medicine and playing an irreplaceable role in the field of regenerative medicine. The US FDA has approved the organization of nearly ten products such as engineered skin and cartilage, and China has also approved the listing of tissue engineering skins. The industry for tissue engineering products has begun to take shape. However, there are standard lags in the technical field of tissue engineering and medical products at home and abroad, which limits the clinical application and industrialization of such products. The technological level of our country in the field of tissue engineering has basically been in line with international standards, and it is at the leading international level in cartilage regeneration and other technical fields. Being a member of ISO/TC150/SC7 will not only enable China to win the right to speak in the field of international standardization activities in this field, but also to participate substantively in the international standard system revision work. It will also promote the development of the tissue engineering medical device industry in China. It will play an important role in enabling people to use high-tech tissue engineering medical products as soon as possible.